Skip To Main Content
Bart Reymen on Muck Rack

Bart Reymen

As seen in: Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bart

Contact Bart, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer

|
By Wouter van Elmpt, Stefania Rizzo, Gianluca Spitaleri, Arthur Jochems, Lizza E. L. Hendriks, Esther G. C. Troost, Anne-Marie C. Dingemans, Philippe Lambin, Anna Colarieti, Ralph T. H. Leijenaar, Bart Reymen
| Lung Cancer Verified
Publication HistoryPublished online: July 20, 2018Accepted: July 17, 2018; Received in revised form: May 19, 2018; Received: April 7, 2018;
Open in Who Shared Issue with article?

PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes

|
By Catharina M.L. Zegers, Bart Reymen, Esther G.C. Troost, Aniek J.G. Even
| tu-dresden.de
Background and purpose We compared two imaging biomarkers for dose-escalation in patients with advanced non-small cell lung cancer (NSCLC). Treatment plans boosting metabolically active sub-volumes defined by FDG-PET or hypoxic sub-volumes defined by HX4-PET were compared with boosting the entire tumour. Materials and methods Ten NSCLC patients underwent FDG- and HX4-PET/CT scans prior to radiotherapy.
Open in Who Shared Issue with article?
See all 2 articles